Finance

Lists
IKT:NASDAQ
Inhibikase Therapeutics Inc
$1.52
-0.98%
(-0.015) 1D
Nov 13, 1:15:32 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for IKT...
Open
$1.56
High
$1.58
Low
$1.48
Mkt. cap
212.51M
Avg. vol.
640.18K
Volume
72.88K
52-wk high
$2.61
52-wk low
$1.40
EPS
-$0.44
Beta
0.94
Shares outstanding
140.27M
No. of employees
35
Open
$1.56
High
$1.58
Low
$1.48
Mkt. cap
212.51M
Avg. vol.
640.18K
Volume
72.88K
52-wk high
$2.61
52-wk low
$1.40
EPS
-$0.44
Beta
0.94
Shares outstanding
140.27M
No. of employees
35
News stories
From web sources and news partners
About Inhibikase Therapeutics Inc
CEO-
Employees35
Founded2008
HeadquartersWilmington, Delaware, United States
SectorHealth Care
IndustryBiotechnology
Websiteinhibikase.com
Analyst ratings
Based on 5 analysts giving stock ratings to IKT in the past 3 months
Strong buy
Buy
4
Hold
1
Sell
0
12-month forecast
Based on 5 Wall Street analysts offering 12 month price targets for IKT in the last 3 months.
Highest
Current $1.52
$8.00 (+428.05%)
Average
$5.50 (+263.04%)
Lowest
$1.50 (-0.99%)
Analyst
Recommendation
Action
Price target
Projected
Date
Ram Selvaraju
H.C. Wainwright
Buy
Reiterated
$8.00
+428.1%
11/13/2026
Jason McCarthy
Maxim Group
Buy
Maintained
$8.00
+428.1%
11/11/2026
Mazahir Alimohamed
Oppenheimer
Buy
Maintained
$5.00
+230%
11/11/2026
Andreas Argyrides
Chardan Capital
Hold
Initiated
$1.50
-1%
10/13/2026
Gaurav Maini
LifeSci Capital
Buy
Maintained
$5.00
+230%
09/15/2026
Jason Zemansky
Bank of America Securities
Buy
Maintained
$6.00
+296%
07/27/2026
Olivia Brayer
Cantor Fitzgerald
Buy
Maintained
$4.00
+164%
05/18/2026
Aydin Huseynov
Ladenburg Thalmann & Co.
Buy
Initiated
$4.00
+164%
03/04/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
-
-
-
-
Cost of goods sold
-21.63M
-
-
-
Cost of revenue
-21.63M
-
-
-
Research and development expenses
22.39M
10.84M
13.39M
15.00M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
6.77M
7.38M
7.66M
7.23M
Operating expense
29.17M
18.22M
21.05M
22.23M
Total operating expenses
7.53M
18.22M
21.05M
22.23M
Operating income
-7.53M
-18.22M
-21.05M
-22.23M
Other non operating income
-
1.46M
1.46M
1.76M
EBT including unusual items
-12.73M
-16.38M
-19.59M
-20.47M
EBT excluding unusual items
-6.49M
-16.75M
-19.59M
-20.47M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-12.73M
-16.38M
-19.59M
-20.47M
Net profit margin
-
-
-
-
Earnings per share
-
-0.10
-0.11
-0.11
Interest and investment income
1.04M
-
-
-
Interest expense
-
-
-
-
Net interest expenses
1.04M
-
-
-
Depreciation and amortization charges
-
-
-
-
EBITDA
-7.53M
-18.20M
-21.04M
-22.21M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps